Orthokeratinized Odontogenic Cyst: A Clinicopathologic Study of 61 Cases

2010 ◽  
Vol 134 (2) ◽  
pp. 271-275 ◽  
Author(s):  
Qing Dong ◽  
Shuang Pan ◽  
Li-Sha Sun ◽  
Tie-Jun Li
Keyword(s):  
Odontogenic Cyst ◽  
World Health ◽  
Keratocystic Odontogenic Tumor ◽  
Impacted Tooth ◽  
Ki 67 ◽  
Orthokeratinized Odontogenic Cyst ◽  
Clinicopathologic Study ◽  
Mandibular Molar ◽  
Health Organization

Abstract Context.—Orthokeratinized odontogenic cyst (OOC) is a relatively uncommon developmental cyst comprising about 10% of cases that had been previously coded as odontogenic keratocysts. Odontogenic keratocyst was designated as keratocystic odontogenic tumor (KCOT) in the new World Health Organization classification and OOC should be distinguished from KCOT for differences in histologic features and biologic behavior. Objective.—To analyze the clinicopathologic features of 61 cases of OOC in a Chinese population. Design.—Clinicopathologic analysis was performed on 61 cases of OOC. Immunohistochemical expression of Ki-67 and p63 was evaluated in 15 OOCs and 15 typical KCOTs. Results.—The 61 patients with OOC ranged from 13 to 75 years (average, 38.93 years). The lesions developed mainly in the third and fourth decades (57.38%) with a distinct predilection for males (72.13%). Six (9.84%) lesions were found in the maxilla and 55 (90.16%) in the mandible. The most common sites were in the mandibular molar and ramus region. Of the 54 cases with radiographic record, 47 (87.04%) were unilocular and 7 (12.96%) were multilocular radiolucencies. Twenty-seven of the 54 cysts were associated with an impacted tooth. Follow-up of 42 patients revealed no recurrence during an average period of 76.8 months after surgery. Compared with KCOTs, expression level of Ki-67 and p63 was significantly lower in OOCs, suggesting a lower proliferative activity. Conclusion.—Orthokeratinized odontogenic cyst is clinicopathologically distinct from KCOT and should constitute its own clinical entity.

scholarly journals Orthokeratinized Odontogenic Cyst

2012 ◽  
Vol 2 (2) ◽  
pp. 31-33 ◽  
Author(s):  
Niharika Swain ◽  
LS Poonja ◽  
Kamlesh Dekate
Keyword(s):  
Granular Cell ◽  
Odontogenic Cyst ◽  
World Health ◽  
Odontogenic Cysts ◽  
Keratocystic Odontogenic Tumor ◽  
Unusual Site ◽  
Orthokeratinized Odontogenic Cyst ◽  
Odontogenic Origin ◽  
Health Organization ◽  
Anterior Mandible

ABSTRACT Orthokeratinized odontogenic cyst (OOC) is a developmental cyst of odontogenic origin and was initially defined as the uncommon orthokeratinized variant of odontogenic keratocyst (OKC). However, recently World Health Organization has designated OOC as a distinct clinicopathologic entity as it has peculiar clinicopathologic aspects when compared to other developmental odontogenic cysts, especially OKCs. The orthokeratinized odontogenic cyst is histologically characterized by a thin, uniform, epithelial lining with orthokeratinization and a subjacent prominent granular cell layer. The purpose of the article is to present a case of OOC arising in the anterior mandible, an unusual site for the lesion and also highlights the importance of distinguishing it from the more commonly occurring keratocystic odontogenic tumor (KCOT). How to cite this article Swain N, Patel S, Poonja LS, Pathak J, Dekate K. Orthokeratinized Odontogenic Cyst. J Contemp Dent 2012;2(2):31-33.

scholarly journals Queratocisto odontogênico: uma abordagem cirúrgica

2020 ◽  
Vol 8 (11) ◽  
Author(s):  
Francielly Thomas Figueiredo ◽  
Alana Oswaldina Gavioli Meira Dos Santos ◽  
Julio Cesar Leite Da Silva ◽  
José Carlos Garcia De Mendonça ◽  
Gustavo Silva Pelissaro ◽  
...  
Keyword(s):  
Head And Neck ◽  
Odontogenic Tumor ◽  
World Health ◽  
Odontogenic Cysts ◽  
Keratocystic Odontogenic Tumor ◽  
Head And Neck Tumours ◽  
Keratocystic Odontogenic Tumour ◽  
Health Organization

O queratocisto odontogênico é uma neoplasia benigna onde lesões únicas ou múltiplas são encontradas em ossos ou cavidades. O objetivo deste trabalho é relatar um caso clínico de uma lesão de queratocisto odontogênico, evidenciando corretos diagnóstico e terapêutica. O relato de caso trata-se de um paciente de 32 anos, sexo feminino, melanoderma, que deu entrada à faculdade de odontologia da Universidade Federal de Mato Grosso do Sul, no ano de 2017, apresentando lesão radiolúcida com halo esclerótico em região de ângulo de mandíbula do lado esquerdo, sem envolvimento de dentes e/ou raízes adjacentes. Foi realizada uma tomografia computadorizada, constando hipótese diagnóstica radiográfica da mencionada patologia. O plano de tratamento adotado preconizou uma intervenção conservadora de descompressão e acompanhamento pós-operatório. A paciente se encontra em pós-operatório de 19 meses cirúrgico sem queixas álgicas e/ou funcionais.Descritores: Cistos Ósseos; Descompressão; Terapêutica.ReferênciasShuster A, Shlomi B, Reiser V, Kaplan I. Solid keratocystic odontogenic tumor report of a non agressive case. J Oral Maxillofac Surg. 2012;70(4):865-70.Tsukamoto G, Sasaki A, Akiyama T, Ishikawa T, Kishimoto K, Nishiyama A, et al. A radiologic analysis of dentigerous cysts and odontogenic keratocysts associated with a mandibular third molar. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91(6):743-47.Chan JKC, El-Naggar AK, Grandis JR, Takata T, Slootweg PJ. Who classification of head and neck tumours. World Health Organization 2017, 4th edition.Wright JM, Vered M. Update from the 4th edition of the world health organization classification of head and neck tumours: odontogenic and maxillofacial bone tumors. Head Neck Pathology. 2017; 11(1): 68-77.Gil JN, Rau Lh, Manfro R, Gasperini G, Dunker C, Chiarelli M. Ceratocisto odontogênico - caso clínico. Rev Port Estomatol Med Dent Cir Maxilofac. 2003;44(3):59-69.Regezi JÁ, Sciubba JJ. Patologia bucal: correlações clinicopatológicas. 3. ed. Rio de Janeiro: Guanabara Koogan; 2000.Larsen PE. Marsupialization for odontogenic keratocysts: Long-term follow-up analysis of the effects and changes in growth characteristics. 2002;94(5):543-53.Gambhir A, Rani G. Conservative management of keratocystic odontogenic tumour with enucleation, excision of the overlying mucosa and electrocauterization: a case report. West Indian Med J. 2014;63(7):775-78.Núñez-Urrutia S, Figueiredo R, Gay-Escoda C. Retrospective clinicopathological study of 418 odontogenic cysts. Med Oral Patol Oral Cir Bucal. 2010;15(5):e767-73.González-Alva P, Tanaka A, Oku Y, Yoshizawa D, Itoh S, Sakashita H, et al. Keratocystic odontogenic tumor: a retrospective study of 183 cases. J Oral Sci. 2008; 50(2):205-12.Jones AV, Craig GT, Franklin CD. Range and demographics of odontogenic cysts diagnosed in a UK population over a 30-year period. J Oral Pathol Med. 2006;35(8):500-7.Zhao YF, Wei JX, Wang SP. Treatment of odontogenic Keratocysts: a follow-up of 255 Chinese patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endodo. 2002;94(2):151-56 .Meara JG, Shah S, Li KK, Cunningham MJ. The odontogenic keratocyst: a 20-year clinicophatologic review. Laryngoscope. 1998;108(2):280-83Kulkarni GH, Khaji SI, Metkari S, Kulkarni HS, Kulkarni R. Multiple keratocysts of the mandible in association with Gorlin-Goltz syndrome: A rare case report. Contemp Clin Dent. 2014;5(3):419-21.Speight PM, Takata T. New tumour entities in the 4th edition of the world health organization classification of head and neck tumours: odontogenic and maxillofacial bone tumours. Virchows Arch. 2018;472(3):331-39.Wright JM. The odontogenic keratocyst: orthokeratinized variant. Oral Surg. 1981;51(1):609-18.Hupp JR, Ellis III E, Tucker MR. Cirurgia oral e maxillofacial contemporânea. 5. ed. Rio de Janeiro: Elsevier; 2009.Dammer R, Niederdellmann H, Dammer P, Nuebler-Moritz M. Conservative or radical tretment of keratocysts: a retrospective review. Br J Oral Maxillofac Surg. 1997;35(1):46-8.Browne RM. The pathogeneses of odontogenic cysts: a review. J Oral Pathol. 1975;4(1):31-46.de Molon RS, Verzola MH, Pires LC, Mascarenhas VI, da Silva RB, Cirelli JA et al. Five years follow-up of a keratocyst odontogenic tumor treated by marsupialization and enucleation: A case report and literature review. Contemp Clin Dent. 2015;6(Suppl 1):S106-10.Neville BW, Damm DD, Allen CM, Bouquot JE. Patologia oral e maxilofacial. 3.ed. Rio de Janeiro: Elsevier; 2009.de Souza LB, Gordón-Núñez MAG, Nonaka CFW, de Medeiros MC, Torres TF, Emiliano GBG. Odontogenic cysts: Demographic profile in a Brazilian population over a 38-year period. Med Oral Patol Oral Cir Bucal. 2010;15(4):e583-90.EL-Gehani R, Orafi M, Elarbi M, Subhashraj K: Benign tumours of orofacial region at Benghazi, Libya: a study of 405 cases. J Craniomaxillofac Surg 2009;37(7):370-75.Moura BS, Cavalcante MA, Hespanhol W. Tumor odontogênico ceratocístico.  Keratocystic odontogenic tumor. Rev Col Bras Cir. 2016;43(6):466-71.Kaczmarzyk T, Mojsa I, Stypulkowska J. A systematic review of the recurrence rate for keratocystic odontogenic tumour in relation to treatment modalities. Int J Oral Maxillofac Surg. 2012;41(6):756-67.Lima GM, Nogueira RLM, Rabenhorst SHB. Considerações atuais sobre o comportamento biológico dos queratocistos odontogênicos. Rev Cir Traumatol Buco-Maxilo-fac. 2006;6(2):9-16.Madras J, Lapointe H. Keratocystic odontogenic tumour: reclassification of the odontogenic keratocyst from cyst to tumour. J Canad Dent Assoc. 2008; 74(2):165-165h.

scholarly journals Expect the unexpected – A rare case of Orthokeratinized Odontogenic Cyst and its surgical management

2021 ◽  
pp. 119-124
Author(s):  
M.M. Sheik Sameerudeen ◽  
◽  
R.N. Mugundan ◽  
S Shwetha ◽  
A. Fahmidha
Keyword(s):  
Surgical Management ◽  
Rare Case ◽  
Odontogenic Cyst ◽  
World Health ◽  
Odontogenic Cysts ◽  
Keratocystic Odontogenic Tumor ◽  
Dental Lamina ◽  
Orthokeratinized Odontogenic Cyst ◽  
Impacted Canine ◽  
Radiolucent Lesion

Orthokeratinized Odontogenic Cyst (OOC) is a rare, developmental odontogenic cyst of the dental lamina. It was initially defined as the uncommon orthokeratinized variant of the Odontogenic Keratocyst (OKC), until the World Health Organization’s (WHO’s) classification in 2005 and 2017, where it was separated from the Keratocystic Odontogenic Tumor (KCOT) and has been included as a separate entity from the category of developmental odontogenic cysts respectively. It presents as a unilocular radiolucent lesion involving the posterior mandible and is frequently related to impacted teeth, often similar to other odontogenic cysts. Due to low local aggressiveness and less proliferative activity, it has to be differentiated from the other cysts in terms of surgical management. Here we report a rare case of OOC involving the maxilla along with an impacted canine and discuss the surgical management and why a secondary surgical intervention is unnecessary.

scholarly journals Keratocystic Odontogenic Tumor

2013 ◽  
Vol 3 (2) ◽  
pp. 87-91
Author(s):  
Jyotsna Galinde ◽  
Sunil Sidana ◽  
Radhika Ramaswami ◽  
N Srivalli
Keyword(s):  
Odontogenic Tumor ◽  
World Health ◽  
Odontogenic Keratocyst ◽  
Keratocystic Odontogenic Tumor ◽  
Carnoy’S Solution ◽  
Good Healing ◽  
Chronic Irritation ◽  
Health Organization ◽  
Histology Report

ABSTRACT In 2005, the World Health Organization renamed the lesion, previously known as an odontogenic keratocyst, as the keratocystic odontogenic tumor (KOT or KCOT). The term odontogenic keratocyst (OKC) was first used by Philipson in 1963 and its clinical and histologic features were confirmed by Browne in 1970 and 1971. In this case report, a young patient with a histology report as an orthokeratinized variety of KCOT and it was a primary lesion with amcystic lining that was thick may be due to chronic irritation because of which it could be removed in toto. Resection was not advocated as it causes morbidity, peripheral ostectomy could not be performed as the buccal and lingual cortical plates were already thinned out with areas of perforation. Thus, enucleation with Carnoy's solution was considered ideal for this case. Also, this patient has been on regular follow-up for around 8 months showed good healing with no signs of recurrence. How to cite this article Ramaswami R, Galinde J, Srivalli N, Sidana S. Keratocystic Odontogenic Tumor. J Contemp Dent 2013;3(2):87-91.

scholarly journals Programme for Harmonization to the International Scale in Latin America for BCR-ABL1 quantification in CML patients: findings and recommendations

2020 ◽  
Vol 58 (12) ◽  
pp. 2025-2035
Author(s):  
María Sol Ruiz ◽  
María Belén Sánchez ◽  
Yuly Masiel Vera Contreras ◽  
Evangelina Agrielo ◽  
Marta Alonso ◽  
...  
Keyword(s):  
Latin America ◽  
Myeloid Leukemia ◽  
World Health ◽  
Molecular Response ◽  
Limit Of Quantification ◽  
International Scale ◽  
Deep Molecular Response ◽  
Health Organization ◽  
First Time

AbstractObjectivesThe quantitation of BCR-ABL1 mRNA is mandatory for chronic myeloid leukemia (CML) patients, and RT-qPCR is the most extensively used method in testing laboratories worldwide. Nevertheless, substantial variation in RT-qPCR results makes inter-laboratory comparability hard. To facilitate inter-laboratory comparative assessment, an international scale (IS) for BCR-ABL1 was proposed.MethodsThe laboratory-specific conversion factor (CF) to the IS can be derived from the World Health Organization (WHO) genetic reference panel; however, this material is limited to the manufacturers to produce and calibrate secondary reference reagents. Therefore, we developed secondary reference calibrators, as lyophilized cellular material, aligned to the IS. Our purpose was both to re-evaluate the CF in 18 previously harmonized laboratories and to propagate the IS to new laboratories.ResultsOur field trial including 30 laboratories across Latin America showed that, after correction of raw BCR-ABL1/ABL1 ratios using CF, the relative mean bias was significantly reduced. We also performed a follow-up of participating laboratories by annually revalidating the process; our results support the need for continuous revalidation of CFs. All participating laboratories also received a calibrator to determine the limit of quantification (LOQ); 90% of them could reproducibly detect BCR-ABL1, indicating that these laboratories can report a consistent deep molecular response. In addition, aiming to investigate the variability of BCR-ABL1 measurements across different RNA inputs, we calculated PCR efficiency for each individual assay by using different amounts of RNA.ConclusionsIn conclusion, for the first time in Latin America, we have successfully organized a harmonization platform for BCR-ABL1 measurement that could be of immediate clinical benefit for monitoring the molecular response of patients in low-resource regions.

scholarly journals Trials and Tribulations: mHealth Clinical Trials in the COVID-19 Pandemic

2021 ◽  
Author(s):  
Praveen Indraratna ◽  
Uzzal Biswas ◽  
Jennifer Yu ◽  
Guenter Schreier ◽  
Sze-Yuan Ooi ◽  
...  
Keyword(s):  
Decompensated Heart Failure ◽  
Hospital Staff ◽  
Outpatient Setting ◽  
World Health ◽  
Randomised Control Trial ◽  
Contact Method ◽  
Model Of Care ◽  
Coronary Syndrome ◽  
Health Organization

Introduction: Mobile phone-based interventions in cardiovascular disease are growing in popularity. A randomised control trial (RCT) for a novel smartphone app-based model of care, named TeleClinical Care - Cardiac (TCC-Cardiac), commenced in February 2019, targeted at patients being discharged after care for an acute coronary syndrome or episode of decompensated heart failure. The app was paired to a digital sphygmomanometer, weighing scale and a wearable fitness band, all loaned to the patient, and allowed clinicians to respond to abnormal readings. The onset of the COVID-19 pandemic necessitated several modifications to the trial in order to protect participants from potential exposure to infection. The use of TCC-Cardiac during the pandemic inspired the development of a similar model of care (TCC-COVID), targeted at patients being managed at home with a diagnosis of COVID-19. Methods: Recruitment for the TCC-Cardiac trial was terminated shortly after the World Health Organization announced COVID-19 as a global pandemic. Telephone follow-up was commenced, in order to protect patients from unnecessary exposure to hospital staff and patients. Equipment was returned or collected by a ‘no-contact’ method. The TCC-COVID app and model of care had similar functionality to the original TCC-Cardiac app. Participants were enrolled exclusively by remote methods. Oxygen saturation and pulse rate were measured by a pulse oximeter, and symptomatology measured by questionnaire. Measurement results were manually entered into the app and transmitted to an online server for medical staff to review. Results: A total of 164 patients were involved in the TCC-Cardiac trial, with 102 patients involved after the onset of the pandemic. There were no hospitalisations due to COVID-19 in this cohort. The study was successfully completed, with only three participants lost to follow-up. During the pandemic, 5 of 49 (10%) of patients in the intervention arm were readmitted compared to 12 of 53 (23%) in the control arm. Also, in this period, 28 of 29 (97%) of all clinically significant alerts received by the monitoring team were managed successfully in the outpatient setting, avoiding hospitalisation. Patients found the user experience largely positive, with the average rating for the app being 4.56 out of 5. 26 patients have currently been enrolled for TCC-COVID. Recruitment is ongoing. All patients have been safely and effectively monitored, with no major adverse clinical events or technical malfunctions. Patient satisfaction has been high. Conclusion: The TCC-Cardiac RCT was successfully completed despite the challenges posed by COVID-19. Use of the app had an added benefit during the pandemic as participants could be monitored safely from home. The model of care inspired the development of an app with similar functionality designed for use with patients diagnosed with COVID-19.

scholarly journals Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts

2016 ◽  
Vol 140 (5) ◽  
pp. 437-448 ◽  
Author(s):  
Joo Young Kim ◽  
Seung-Mo Hong
Keyword(s):  
World Health Organization ◽  
Neuroendocrine Tumors ◽  
Classification Scheme ◽  
Neuroendocrine Cells ◽  
Labeling Index ◽  
World Health ◽  
World Health Organization Classification ◽  
Clinicopathologic Characteristics ◽  
Ki 67 ◽  
Health Organization

Context.—Gastrointestinal (GI) and pancreatobiliary tracts contain a variety of neuroendocrine cells that constitute a diffuse endocrine system. Neuroendocrine tumors (NETs) from these organs are heterogeneous tumors with diverse clinical behaviors. Recent improvements in the understanding of NETs from the GI and pancreatobiliary tracts have led to more-refined definitions of the clinicopathologic characteristics of these tumors. Under the 2010 World Health Organization classification scheme, NETs are classified as grade (G) 1 NETs, G2 NETs, neuroendocrine carcinomas, and mixed adenoneuroendocrine carcinomas. Histologic grades are dependent on mitotic counts and the Ki-67 labeling index. Several new issues arose after implementation of the 2010 World Health Organization classification scheme, such as issues with well-differentiated NETs with G3 Ki-67 labeling index and the evaluation of mitotic counts and Ki-67 labeling. Hereditary syndromes, including multiple endocrine neoplasia type 1 syndrome, von Hippel-Lindau syndrome, neurofibromatosis 1, and tuberous sclerosis, are related to NETs of the GI and pancreatobiliary tracts. Several prognostic markers of GI and pancreatobiliary tract NETs have been introduced, but many of them require further validation. Objective.—To understand clinicopathologic characteristics of NETs from the GI and pancreatobiliary tracts. Data Sources.—PubMed (US National Library of Medicine) reports were reviewed. Conclusions.—In this review, we briefly summarize recent developments and issues related to NETs of the GI and pancreatobiliary tracts.

Overexpression of Cyclin A and Cyclin B1Proteins in Astrocytomas

2000 ◽  
Vol 124 (2) ◽  
pp. 216-220 ◽  
Author(s):  
Katherine Allan ◽  
Richard C. K. Jordan ◽  
Lee-Cyn Ang ◽  
Michael Taylor ◽  
Beverley Young
Keyword(s):  
Indirect Evidence ◽  
Tumor Grade ◽  
Cyclin A ◽  
Cyclin B1 ◽  
Histologic Grade ◽  
World Health ◽  
Poor Correlation ◽  
Surgical Biopsy ◽  
Ki 67 ◽  
Health Organization

Abstract Background.—Cyclins are proteins that are expressed during the progression of a normal cell through the cell cycle. In a number of cancers, overexpression of cyclin A and cyclin B1 proteins has been reported, and in some instances the levels of expression correlated well with the grades of malignancy. The expression of cyclin A and cyclin B1 proteins in astrocytoma may be linked to the histologic grade or proliferative activities. Objective.—To study the expression of cyclin A and cyclin B1 proteins in astrocytomas and correlate the labeling indices (LIs) of cyclin A and cyclin B1 with histologic grade and Ki-67 LI. Design.—The surgical biopsy specimens from 65 adults with astrocytomas were reviewed and divided into grades based on the World Health Organization system. The paraffin sections were immunostained using primary antibodies against Ki-67, cyclin A, and cyclin B1. The LIs of these astrocytomas for the 3 different antibodies were determined by computerized image analysis. Results.—The cyclin A LI showed good correlation with astrocytoma grade and Ki-67 LI. Both the nuclear and cytoplasmic cyclin B LIs correlated well with the tumor grade but showed poor correlation with Ki-67 LI. Conclusions.—This study suggests that although both cyclin A and B protein expression are related to the grade of malignancy in astrocytomas, cyclin A levels more generally reflect the proliferative state of these tumors. We also provide indirect evidence that cyclin B1 is associated with the aberrant progression through the G2-M phase checkpoint in astrocytomas.

Reasons for Vaccine Rejection in 0 to 2 Years Old Children Registered to Family Health Centers in Konya

2021 ◽  
Vol 16 (02) ◽  
pp. 074-079
Author(s):  
Hasan Kucukkendirci ◽  
Fatih Kara ◽  
Gulsum Gulperi Turgut
Keyword(s):  
Health Personnel ◽  
Family Health ◽  
Cross Sectional Study ◽  
World Health ◽  
University Graduates ◽  
Cross Sectional ◽  
Vaccination Programs ◽  
Vaccine Preventable Diseases ◽  
Health Organization

AbstractObjective According to the 2017 report of the World Health Organization (WHO), ∼1.5 million people die from vaccine preventable diseases. The WHO is working to generate and popularize effective vaccination programs. However, the concept of “vaccine rejection,” which first started in Europe and United States, has started to make an impact in Turkey during the past 10 years. It is therefore seen as a growing danger in future. This study was conducted to determine, detect, and prevent the reasons of vaccine rejection that have increased in recent years.Methods A cross-sectional study was conducted between June and December at 2015. In all districts of Konya (n = 31), it was aimed to reach all 242 families who rejected vaccination to their 0 to 2 years old babies. Families having more than one child refused to vaccinate all of their children. A questionnaire consisting of 47 questions was prepared by the researchers, using the standard trainings of the Ministry of Health and the literature. A total of 172 families agreed to participate in this study. The questionnaire was applied to the parents using the telephone interview technique. Data were presented as mean ± standard deviation and percentage.Results About 41.3% (n = 71) of the mothers were high school graduates, 50.6% (n = 87) of their fathers were university graduates. About 82.6% (n = 142) of the participants received examination, treatment and follow-up services from family physicians and family health personnel. About 20.9% (n = 36) of the children were the only children of the family. About 55.8% (n = 96) of the families also refused the vaccination for other children. About 83.7% (n = 144) of the unvaccinated children had infants/children follow-up care. While all participants stated that vaccines had side effects, 31.4% (n = 54) of these believed that vaccines cause autism or paralysis in infants. About 62.2% (n = 107) of their mothers did not receive tetanus vaccine during pregnancy. The highest rate of nonvaccination was with the second dose of hepatitis A vaccine, which 96.5% (n = 166) refused. The most accepted vaccine was the first dose of hepatitis B vaccine, which was refused by 18.0% (n = 31). About 79.7% (n = 137) of the participants did not know the reason for the vaccination and 95.9% (n = 165) thought that the vaccines were not required. All participants received information from the health personnel about the vaccines. While 9.9% (n = 17) of the families thought that vaccines cause infertility, 44.8% (n = 77) did not receive vaccination because the vaccines were produced abroad.Conclusion A growing number of families refuse to have their babies vaccinated. The production of vaccines abroad is a major cause of insecurity. There are also beliefs that vaccines cause infertility. Vaccine production in Turkey should be accelerated and public education about vaccines should be reviewed. Training provided to families about vaccines should also be reviewed.

scholarly journals Testing brief intervention and phone contact among subjects with suicidal behavior: a randomized controlled trial in French Polynesia in the frames of the World Health Organization/Suicide Trends in At-Risk Territories study

2015 ◽  
Vol 7 (2) ◽  
Author(s):  
Stéphane Amadéo ◽  
Moerani Rereao ◽  
Aurelia Malogne ◽  
Patrick Favro ◽  
Ngoc Lam Nguyen ◽  
...  
Keyword(s):  
At Risk ◽  
World Health Organization ◽  
Brief Intervention ◽  
Suicidal Behavior ◽  
French Polynesia ◽  
World Health ◽  
Suicidal Behaviors ◽  
The World ◽  
Health Organization

The World Health Organization <em>Suicide trends in at-risk territories</em> study is a multi-site regional research program operating first in French Polynesia and countries of the Western Pacific, then extended to the world. The aims of the study were to establish a monitoring system for suicidal behaviors and to conduct a randomised control trial intervention for non-fatal suicidal behaviors. The latter part is the purpose of the present article. Over the period 2008-2010, 515 patients were admitted at the Emergency Department of the Centre Hospitalier de Polynésie Française for suicidal behavior. Those then hospitalized in the Psychiatry Emergency Unit were asked to be involved in the study and randomly allocated to either Treatment As Usual (TAU) or TAU plus Brief Intervention and Contact (BIC), which provides a psycho-education session and a follow-up of 9 phone contacts over an 18-months period. One hundred persons were assigned to TAU, while 100 participants were allocated to the BIC group. At the end of the follow-up there were no significant differences between the two groups in terms of number of presentations to the hospital for repeated suicidal behaviors. Although the study could not demonstrate the superiority of a treatment over the other, nevertheless – given its importance – the investigation captured public attention and was able to contribute to the awareness of the need of suicide prevention in French Polynesia. The BIC model of intervention seemed to particularly suit the geographical and health care context of the country.

Sign in / Sign up

Export Citation Format

Share Document